Clinical Trial Update: A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of tislelizumab plus axitinib as neoadjuvant therapy for clear cell renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Hongqian Guo | Conditions: Neoadjuvant Therapy | Phase 2 | Status: UNKNOWN